---
title: "Descartes-08 in Generalized myasthenia gravis: Product comparison"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Product comparison. Topics: Descartes-08: mechanism, route, dosing schedule, and approval status; Complement C5 inhibitor: Soliris; Complement C5 inhibitor: Ultomiris; Complement C5 inhibitor: Zilbrysq; 6 further topics. 10 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/product-comparison"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Descartes-08: mechanism, route, dosing schedule, and approval status

| Attribute | Quoted text |
| --- | --- |
| Product | “Descartes-08, our lead cell therapy product candidate, is an autologous CAR-T product targeting B-cell maturation antigen, or BCMA, in clinical development for the treatment of MG and myositis, specifically, moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome.” |
| Mechanism of action | “Descartes-08 is specifically designed to target and destroy the pathogenic, self-reactive cells that are the underlying cause of the autoimmune disease, with the goal of creating a precision immune reset for the patient.” |
| Route and dosing schedule | “Once the manufacturing process is complete, we send the product candidate back to the treating physician where they administer six weekly infusions of our cell therapy to the patient.” |
| Dose | “Patients received six weekly infusions at the dose established in Phase 1b (52.5 x10⁶ cells/kg).” |
| Preconditioning and care setting | “In contrast to conventional DNA-based CAR T-cell therapies, our CAR-T administration has been observed to provide deep and durable benefits through 12 months, is designed to not require preconditioning chemotherapy, to be administered in the outpatient setting and does not carry the risk of genomic integration associated with cancerous transformation.” |
| Approval status | “Our most advanced product candidate, Descartes-08, is in Phase 3 clinical development.” |

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.2.14-2"></a>

### Complement C5 inhibitor: Soliris

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “SOLIRIS® (eculizumab) injection, for intravenous use” |
| gMG indication | “the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine receptor (AChR) antibody positive.” |
| Mechanism of action | “Eculizumab, the active ingredient in SOLIRIS, is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9.” |
| Adult dosing and interval in gMG | “900 mg weekly for the first 4 weeks, followed by” |
| Adult dosing and interval in gMG, continued | “1,200 mg every 2 weeks thereafter.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2007” |

Source: [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)

<a id="topic-2.1.2.14-3"></a>

### Complement C5 inhibitor: Ultomiris

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “ULTOMIRIS® (ravulizumab-cwvz) injection, for intravenous use” |
| gMG indication | “the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.” |
| Mechanism of action | “Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity” |
| Dosing interval | “maintenance doses administered every 4 or 8 weeks, starting 2 weeks after loading dose.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2018” |

Source: [Ultomiris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761108s046lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

### Complement C5 inhibitor: Zilbrysq

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “ZILBRYSQ® (zilucoplan) injection, for subcutaneous use” |
| gMG indication | “ZILBRYSQ is a complement inhibitor indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.” |
| Mechanism of action | “Zilucoplan binds to the complement protein C5 and inhibits its cleavage to C5a and C5b, preventing the generation of the terminal complement complex, C5b-9.” |
| Dosing interval | “The recommended dosage of ZILBRYSQ is given once daily as a subcutaneous injection and is dependent on actual body weight” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |

Source: [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

### Neonatal Fc receptor blocker: Vyvgart

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “VYVGART® (efgartigimod alfa-fcab) injection, for intravenous use” |
| gMG indication | “VYVGART is a neonatal Fc receptor blocker indicated for the treatment of adult patients with generalized myasthenia gravis (gMG).” |
| Mechanism of action | “Efgartigimod alfa-fcab is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Dosing and interval | “The recommended dosage is 10 mg/kg administered as an intravenous infusion over one hour once weekly for 4 weeks.” |
| Treatment cycles | “Administer subsequent treatment cycles based on clinical evaluation.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2021” |

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

### Neonatal Fc receptor blocker: Vyvgart Hytrulo

| Attribute | Prescribing information |
| --- | --- |
| Product | “VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase” |
| gMG indication | “generalized myasthenia gravis (gMG)” |
| Mechanism of action | “Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Route | “VYVGART HYTRULO is for subcutaneous use only.” |
| Self-administration | “Prefilled syringe can be administered by patients and/or caregivers.” |
| gMG dosing interval | “Administer in cycles of once weekly injections for 4 weeks.” |
| gMG dose, prefilled syringe | “Prefilled syringe: 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase administered over 20 to 30 seconds.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |

Source: [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

### Neonatal Fc receptor blocker: Rystiggo

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “RYSTIGGO® (rozanolixizumab-noli) injection, for subcutaneous use” |
| gMG indication | “RYSTIGGO (rozanolixizumab-noli) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.” |
| Mechanism of action | “Rozanolixizumab-noli is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Dosing interval | “The recommended dosage is administered as a subcutaneous infusion once weekly for 6 weeks.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

### Neonatal Fc receptor blocker: Imaavy

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “IMAAVY® (nipocalimab-aahu) injection, for intravenous use” |
| gMG indication | “generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.” |
| Mechanism of action | “Nipocalimab-aahu is a human IgG1 monoclonal antibody that binds to neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG levels.” |
| Dosing and interval | “gMG: The recommended initial dosage is 30 mg/kg once via intravenous infusion over at least 30 minutes. Two weeks after the initial dosage, administer a maintenance dosage of 15 mg/kg via intravenous infusion over at least 15 minutes, and continue every two weeks thereafter.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2025” |

Source: [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

### CD19-directed B-cell depleting antibody: Uplizna

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “UPLIZNA® (inebilizumab-cdon) injection, for intravenous use” |
| gMG indication | “Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive.” |
| Mechanism of action | “The mechanism by which inebilizumab-cdon exerts its therapeutic effects in NMOSD, IgG4-RD, and gMG is presumed to involve binding to CD19, a cell surface antigen presents on pre-B and mature B lymphocytes.” |
| Initial dosing | “Initial dose: 300 mg intravenous infusion followed two weeks later by a second 300 mg intravenous infusion.” |
| Dosing interval | “Subsequent doses (starting 6 months from the first infusion): single 300 mg intravenous infusion every 6 months.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2020” |

Source: [Uplizna prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761142s004lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

### Complement C5 inhibitor: Klygefa

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “KLYGEFA™ (gefurulimab-gaks) injection, for subcutaneous use” |
| gMG indication | “KLYGEFA is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.” |
| Mechanism of action | “Gefurulimab-gaks is a terminal complement inhibitor that specifically binds both complement protein C5 and serum albumin.” |
| Dosing | “The recommended dosage of KLYGEFA is dependent on body weight and administered as a subcutaneous injection as shown in Table 1.” |
| Dosing interval | “The weekly maintenance dosage of KLYGEFA may be administered 1 day before the scheduled dose.” |
| Self-administration | “KLYGEFA is intended to be self-administered by the patient or injected by a caregiver.” |
| Restricted distribution | “KLYGEFA is available only through a restricted program called KLYGEFA REMS.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2026” |

Source: [Klygefa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761488s000lbl.pdf)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
